GSK's booklet is quite the tonic

January 2003
Employee Benefits;Jan2003, p26
Reports on GlaxoSmithKline PLC vice president of benefits Rob Collinge's comments on the company's policy on executive remuneration. Basis of remuneration levels; Measurement of human resources elements that create shareholder value.


Related Articles

  • GARNIER GARNERS BRICKBATS. M.J. // Global Finance;Dec2002, Vol. 16 Issue 12, p8 

    Reports on the request of chief executive officer Jean-Pierre Garnier of GlaxoSmithKline for an increased compensation package in the U.S. Objection of the shareholders; Improvement of the pay package; Occurrence of wage inflation.

  • The human factor. Wheatcroft, Patience // Management Today;Jul2003, p25 

    The article author is of the view that while being the best-paid executive is appreciable, what is not equally appreciable is to benefit mostly from failures. The author illustrates the point with an event involving pharmaceutical company GlaxoSmithKline PLC (GSK). Even though investors of GSK...

  • Fat-cat salaries are the best way to get the cream. Pitcher, George // Marketing Week;5/29/2003, Vol. 26 Issue 22, p27 

    Focuses on the salary of executives in Great Britain. Increase in the remuneration received by executives in the oil industry as a result of the Iraq conflict; Dissention of the public, especially the press, against the increase in pay received by executives; Issue concerning the proposed pay...

  • Greed is not good. Catalano, Alex // EG: Estates Gazette;5/24/2003, Issue 321, p38 

    Reports on the implication of the decision of investing institutions to publicly confront the management of a company over boardroom pay for corporate governance. Decision of the shareholders of GlaxoSmithKline to reject a pay policy for the company's executives; Range of salaries of executives...

  • Compliance Kultur The Facts Behind GSK's CIA. Comer, Ben // Pharmaceutical Executive;Aug2012, Vol. 32 Issue 8, p42 

    The article reports on GlaxoSmithKline's (GSK) corporate integrity agreement (CIA) in the U.S. It mandates the GSK to establish a program that puts at risk of forfeiture and recoupment an amount equivalent to up to three years of annual performance pay for an executive who is involved in...

  • GSK Revisits Exec Pay. Houlton, Sarah // Pharmaceutical Executive;Feb2004, Vol. 24 Issue 2, p28 

    Reports on the plan created by GlaxoSmithKline PLC for compensating senior executives to replace a plan rejected by stockholders in Great Britain. Problem of investors with the original proposal; Changes made to the contracts of other executive directors; Salary and bonus package received by...

  • Fat cat cream goes sour.  // European Chemical News;5/26/2003, Vol. 78 Issue 2054, p5 

    Comments on the decision of GlaxoSmithKline (GSK) shareholders to vote down the proposed remuneration package for chief executive officer Jean-Pierre Garnier. Amount of the proposed package; Argument of shareholders against the proposal; Implication of the GSK vote.

  • It's all in the contract. Saunders, Andrew // Management Today;Nov2003, p60 

    The article discusses about inclemency of the economic climate and increasingly strict rules on the disclosure of senior executive pay. J. P. Garnier at GlaxoSmithKline PLC and William Aldinger at HSBC company both had a hard time persuading investors earlier in 2003 that they really deserved...

  • A fine old mess.  // TCE: The Chemical Engineer;Aug2012, Issue 854, p5 

    The article reports that pharmaceuticals company GlaxoSmithKline (GSK) agreed to pay three billion U.S. dollars to settle the fraud case filed against the company in the U.S. The fine include one billion U.S. dollar in criminal fines for marketing its Paxil and Wellbutrin drugs for unapproved...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics